Antigen Binders Specific For IL-23R And Uses Thereof
AssigneeSangamo Therapeutics, Inc.
InventorsTobias ABEL, Maurus DE LA ROSA, David FENARD, Julie GERTNER-DARDENNE
Life of this patent
Estimating the term…
Abstract
IL23R overexpression has been described as a common feature of pathogenic inflammatory cells involved in the onset and maintenance of autoimmune diseases and chronic inflammation. The present disclosure relates to a novel antigen binder directed to IL-23R, to compositions that comprise said antigen binder, and to the use of said antigen binder. The present disclosure further relates to fusion proteins comprising said antigen binder, such as, for example, chimeric antigen receptors.
Claims31
An isolated anti-IL-23 receptor (IL-23R) antibody or antigen-binding fragment thereof, wherein
- the heavy chain variable region (VH) of the antibody or fragment comprises complementary-determining regions (HCDRs) 1-3 comprising SEQ ID NOs:
- 1-3, respectively;
- or any HCDR having an amino acid sequence that shares at least about 90% of identity with one of SEQ ID NOs:
- 1-3;
- and
- the light chain variable region (VL) of the antibody or fragment comprises complementary-determining regions (LCDRs) 1-3 comprising SEQ ID NOs:
- 4-6, respectively;
- or any LCDR having an amino acid sequence that shares at least about 90% of identity with one of SEQ ID NOs:
- 4-6.
An isolated anti-IL-23 receptor (IL-23R) antibody or antigen-binding fragment thereof, wherein
- the heavy chain variable region (VH) of the antibody or fragment comprises complementary-determining regions (HCDRs) 1-3 comprising SEQ ID NOs:
- 1-3, respectively;
- and the light chain variable region (VL) of the antibody or fragment comprises complementary-determining regions (LCDRs) 1-3 comprising SEQ ID NOs:
- 4-6, respectively.
A chimeric antigen receptor (CAR) comprising:
- (i) an anti-IL-23R scFv, optionally comprising SEQ ID NO:
- 15,
- (ii) a hinge domain derived from human CD8, optionally comprising SEQ ID NO:
- 20,
- (iii) a transmembrane domain derived from human CD8, optionally comprising SEQ ID NO:
- 22,
- (iv) an intracellular signaling domain comprising a human CD28 costimulatory signaling domain, optionally comprising SEQ ID NO:
- 32, and a human CD3 zeta domain, optionally comprising SEQ ID NO:
- 30, and
- (v) optionally a tag and/or a leader sequence.
A chimeric antigen receptor (CAR) comprising:
- (i) an anti-IL-23R scFv, optionally comprising SEQ ID NO:
- 15,
- (ii) a hinge domain derived from human CD8, optionally comprising SEQ ID NO:
- 20,
- (iii) a transmembrane domain derived from human CD8, optionally comprising SEQ ID NO:
- 22,
- (iv) an intracellular signaling domain comprising a human CD28 costimulatory signaling domain, optionally comprising SEQ ID NO:
- 32, and a human CD3 zeta domain, optionally comprising SEQ ID NO:
- 30, and
- (v) a leader sequence derived from CD8, optionally comprising SEQ ID NO:
- 40.
A chimeric antigen receptor (CAR) comprising:
- (i) an anti-IL-23R scFv, optionally comprising SEQ ID NO:
- 15,
- (ii) a hinge domain derived from human CD8, optionally comprising SEQ ID NO:
- 20,
- (iii) a transmembrane domain derived from human CD8, optionally comprising SEQ ID NO:
- 22,
- (iv) an intracellular signaling domain comprising a human CD28 costimulatory signaling domain, optionally comprising SEQ ID NO:
- 32, and a human CD3 zeta domain, optionally comprising SEQ ID NO:
- 30, and
- (v) a leader sequence derived from CD25, optionally comprising SEQ ID NO:
- 58.
(canceled)
Dependencies are inferred from the claim text.